Optimization of Antiviral Therapy of Chronic HBV Infection
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Along with the improvement of the accuracy of detection of HBV serological markers, the
optimization of antiviral therapy for patients with chronic hepatitis B (CHB) infection
becomes feasible. Currently, the recommendation of optimized treatment especially interferon
therapy are mainly based on retrospective studies, it still lacks prospective evidence. This
study is aimed to evaluate the efficacy, safety and pharmacoeconomics benefits of 48 weeks
optimized interferon therapy (switch to telbivudine or plus adefovir dipivoxil) for HBeAg
positive CHB with inadequate response to 24 weeks interferon treatment.